Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

EHA 2015

11 - 14 Jun 2015

Published: 12 Jun 2015

Views: 1951

Rating:

Save

Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

Dr Meletios Dimopoulos talks to ecancertv at EHA 2015 about the results of ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone and is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read the news article for more.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

More effective treatment options required for patients with MM post...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

More effective treatment options required for patients with MM post lenalidomide exposure ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

More from ecancer